104 related articles for article (PubMed ID: 6771918)
1. [Plasma testosterone: a sound criterion of the effectiveness of hormonal treatment of prostatic carcinoma].
Maleeva A; Tsvetkov M; Kekhaĭova M
Vutr Boles; 1980; 19(3):42-6. PubMed ID: 6771918
[TBL] [Abstract][Full Text] [Related]
2. [Value of testosterone, FSH and LH on plasma in patients with prostatic adenoma and carcinoma before and after different hormonal treatments].
Garcia de la Peña E; Ramos F; Horcajada C; Cifuentes Delatte L; Vivanco F
Rev Clin Esp; 1978 Jan; 148(1):19-23. PubMed ID: 76325
[No Abstract] [Full Text] [Related]
3. Hormonal predictors of prostate cancer.
Sofikerim M; Eskicorapci S; Oruç O; Ozen H
Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
[TBL] [Abstract][Full Text] [Related]
4. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
Kobayashi T; Nishizawa K; Mitsumori K
Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
[TBL] [Abstract][Full Text] [Related]
5. [Hormonal environment and antiandrogenic treatment in benign prostatic hypertrophy].
Katayama T; Umeda K; Kazama T
Hinyokika Kiyo; 1986 Nov; 32(11):1584-9. PubMed ID: 2435122
[TBL] [Abstract][Full Text] [Related]
6. [Hormonal environment following treatment with a small dose of estrogen--small dose of estrogen alone and in combination with an anti-androgen].
Hayashi T; Taki Y; Ikai K; Hiura M; Kiriyama T
Hinyokika Kiyo; 1987 Jul; 33(7):1035-42. PubMed ID: 2446483
[TBL] [Abstract][Full Text] [Related]
7. [Significance of serum testosterone and LH determination in the hormonal therapy of prostatic cancer].
Scheinar J; Hruska F; Talas M; Janousková M; Fingerová H
Rozhl Chir; 1978 Dec; 57(12):805-12. PubMed ID: 734535
[No Abstract] [Full Text] [Related]
8. The hormonal effects of antiandrogen (SH-714) treatment in man.
Schoonees R; Schalch DS; Murphy GP
Invest Urol; 1971 May; 8(6):635-9. PubMed ID: 5578209
[No Abstract] [Full Text] [Related]
9. Androgen level variations, clinical response to LHRH agonists and changes in the quality of life subscales in metastatic prostate cancer--speculations about possible role of the monoamine system.
Popov I; Jelić S; Radosavljević D; Nikolić-Tomasević Z
Neoplasma; 1997; 44(5):308-13. PubMed ID: 9473791
[TBL] [Abstract][Full Text] [Related]
10. Testosterone recovery following prolonged adjuvant androgen ablation for prostate carcinoma.
Pickles T; Agranovich A; Berthelet E; Duncan GG; Keyes M; Kwan W; McKenzie MR; Morris WJ;
Cancer; 2002 Jan; 94(2):362-7. PubMed ID: 11900222
[TBL] [Abstract][Full Text] [Related]
11. [Hormonal changes in carcinoma of the prostate].
Rodrigues-Netto Júnior N; Da Silva RP; Hernández AJ
Rev Paul Med; 1979; 94(1-2):24-6. PubMed ID: 120973
[No Abstract] [Full Text] [Related]
12. The effects of orchidectomy, estrogens, and cyproterone acetate on plasma testosterone, LH, and FSH concentrations in patients with carcinoma of the prostate.
Varenhorst E; Wallentin L; Carlström K
Scand J Urol Nephrol; 1982; 16(1):31-6. PubMed ID: 6211762
[TBL] [Abstract][Full Text] [Related]
13. [Clinical evaluation of enantone in the treatment of prostate cancer].
Zhang L; Tao D; Wang S
Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):218-20. PubMed ID: 10920902
[TBL] [Abstract][Full Text] [Related]
14. [Effects of oestrogens on cardiovascular risk factors in patients with carcinoma of the prostate (author's transl)].
Varenhorst E; Carlström K; Karlberg BE; Risberg B; Wallentin L; Wranne B
Urologe A; 1982 Jan; 21(1):34-8. PubMed ID: 6805122
[TBL] [Abstract][Full Text] [Related]
15. Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
Kaku H; Saika T; Tsushima T; Ebara S; Senoh T; Yamato T; Nasu Y; Kumon H
Prostate; 2006 Mar; 66(4):439-44. PubMed ID: 16329145
[TBL] [Abstract][Full Text] [Related]
16. An implant releasing the gonadotropin hormone-releasing hormone agonist histrelin maintains medical castration for up to 30 months in metastatic prostate cancer.
Chertin B; Spitz IM; Lindenberg T; Algur N; Zer T; Kuzma P; Young AJ; Catane R; Farkas A
J Urol; 2000 Mar; 163(3):838-44. PubMed ID: 10687989
[TBL] [Abstract][Full Text] [Related]
17. Reversibility of androgen deprivation therapy in patients with prostate cancer.
Fridmans A; Chertin B; Koulikov D; Lindenberg T; Gelber H; Leiter C; Farkas A; Spitz IM
J Urol; 2005 Mar; 173(3):784-9. PubMed ID: 15711270
[TBL] [Abstract][Full Text] [Related]
18. FSH and LH elevation after radiation for treatment of cancer of the prostate.
Seal US
Invest Urol; 1979 Jan; 16(4):278-80. PubMed ID: 429120
[TBL] [Abstract][Full Text] [Related]
19. Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: a prospective study.
Pathak AS; Pacificar JS; Shapiro CE; Williams SG
J Urol; 2007 Jun; 177(6):2132-5; discussion 2135. PubMed ID: 17509298
[TBL] [Abstract][Full Text] [Related]
20. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]